

Acute Cholecystitis Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Type (Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis) By Cause (Gall Bladder Stones, Tumor, Bile Duct Blockage, Microbial Infection, Others) By Diagnostic Procedure (Ultrasonography, Cholescintigraphy, CT Scan, ERCP (Endoscopic Retrograde Cholangiopancreatography), Others) By Treatment (Surgical v/s Non-Surgical) By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others) By Region & Competition, 2021-2031F

<https://marketpublishers.com/r/ABAAF3BC275BEN.html>

Date: January 2026

Pages: 185

Price: US\$ 4,500.00 (Single User License)

ID: ABAAF3BC275BEN

Abstracts

The Global Acute Cholecystitis Market is projected to expand from USD 2.64 Billion in 2025 to USD 3.73 Billion by 2031, reflecting a CAGR of 5.93%. This growth is rooted in the management of acute gallbladder inflammation, a condition primarily triggered by gallstone obstruction of the cystic duct that necessitates urgent diagnosis and treatment. Market expansion is heavily influenced by the escalating incidence of gallstone disease, which is closely tied to an aging global demographic and rising obesity rates, alongside the broader application of minimally invasive surgical options like laparoscopic and robotic cholecystectomy that enhance patient recovery.

Conversely, a significant hurdle limiting market efficiency is the ambiguity often found in standard imaging results, which can result in treatment delays and higher complication

risks. This lack of initial diagnostic clarity represents a substantial gap in the care continuum. Highlighting this issue, the Infectious Diseases Society of America reported in 2024 that the median sensitivity of abdominal ultrasound for detecting suspected acute cholecystitis was only 73%. Such data emphasizes the critical need for superior diagnostic technologies to surpass the constraints of current standard imaging protocols.

Market Driver

The primary catalyst for market revenue is the growing prevalence of gallstones and related disorders, which directly fuels the global volume of cholecystectomy surgeries. This momentum is further accelerated by lifestyle changes and demographic trends, specifically obesity, which make larger populations susceptible to biliary issues, thereby forcing healthcare systems to expand their acute management capacities. As noted by the National Institutes of Health in an October 2025 systematic review titled 'Estimating global prevalence of gallbladder stones in general population from 2000 to 2024,' the global prevalence of gallstones was determined to be 5.86%, ensuring a steady demand for acute care and underpinning long-term market stability.

In parallel, the shift toward laparoscopic and robotic cholecystectomy is redefining the therapeutic sector, increasing market value through the deployment of sophisticated surgical tools. These minimally invasive methods are now the gold standard due to their ability to shorten hospital stays and lower complication rates, which facilitates higher procedural volume. For instance, Intuitive Surgical's 'Preliminary Fourth Quarter and Full Year 2024 Results' from January 2025 indicated a 17% year-over-year increase in procedures using da Vinci systems. However, economic considerations persist; an April 2025 American College of Surgeons study revealed that robotic cholecystectomy involves significantly higher disposable costs at \$1,309 compared to \$534 for traditional laparoscopic methods, delineating a market split between high-volume standard care and premium technological interventions.

Market Challenge

The primary obstacle restricting the Global Acute Cholecystitis Market is the diagnostic uncertainty inherent in conventional imaging techniques. This lack of early precision forms a bottleneck in patient care, frequently leading to hesitation regarding the need for immediate surgery. When primary diagnostic tools like abdominal ultrasound fail to yield clear results, physicians often default to conservative management instead of performing a cholecystectomy, delaying the market's primary revenue-generating

procedure and straining healthcare resources through extended hospitalizations.

The consequences of this diagnostic ambiguity are manifested in high treatment failure rates among patients initially treated non-surgically due to inconclusive tests. Data from the American College of Surgeons in 2024 showed that 78% of patients with acute cholecystitis symptoms who were discharged without surgery eventually required emergency readmission for a cholecystectomy. This pattern highlights a major market inefficiency, where the failure to accurately diagnose and treat the condition during the initial visit results in fragmented care and missed therapeutic opportunities, thereby hindering the seamless adoption of surgical solutions and overall market growth.

Market Trends

A significant trend is the rise of Endoscopic Ultrasound-Guided Gallbladder Drainage (EUS-GBD), specifically using Lumen-Apposing Metal Stents (LAMS), as a transformative approach for patients ineligible for surgery. This technique provides a minimally invasive substitute for percutaneous cholecystostomy, catering to high-risk elderly or comorbid patients unable to tolerate standard cholecystectomy, thereby improving quality of life by internalizing drainage. Validating this approach, a February 2024 study in *Diagnostics* titled 'EUS-Guided Gallbladder Drainage Using a Lumen-Apposing Metal Stent for Acute Cholecystitis' reported a 94% technical success rate for LAMS placement in high-risk groups, establishing it as an effective therapeutic standard.

Concurrently, the incorporation of Artificial Intelligence (AI) into diagnostic imaging is setting new benchmarks for early and precise detection, addressing the shortcomings of traditional ultrasound. By utilizing machine learning to automate pathology recognition and gallbladder segmentation, medical providers can mitigate inter-operator variability and the low sensitivity associated with standard imaging, facilitating quicker intervention decisions. As reported in the *Biomedical Journal of Scientific & Technical Research* in February 2024, the application of specific AI models in the study 'Usage of Artificial Intelligence in Gallbladder Segmentation to Diagnose Acute Cholecystitis' achieved a diagnostic accuracy of 84.09%, presenting a superior alternative to the lower sensitivity found in manual ultrasonography.

Key Market Players

Boston Scientific Corporation

Fresenius Kabi AG

Pfizer Inc

Teva Pharmaceutical Industries Ltd.

Glenmark Pharmaceuticals Limited

Merck & Co. Inc.

Becton, Dickinson and Company

Simulab Corporation

AbbVie Inc.

Fortimedix Surgical BV

Report Scope

In this report, the Global Acute Cholecystitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Cholecystitis Market, By Type

Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis

Acute Cholecystitis Market, By Cause

Gall Bladder Stones

Tumor

Bile Duct Blockage

Microbial Infection

Others

Acute Cholecystitis Market, By Diagnostic Procedure

Ultrasonography

Cholescintigraphy

CT Scan

ERCP (Endoscopic Retrograde Cholangiopancreatography)

Others

Acute Cholecystitis Market, By Treatment

Surgical v/s Non-Surgical

Acute Cholecystitis Market, By End User

Hospitals & Clinics

Ambulatory Surgical Centers

Others

Acute Cholecystitis Market, By Region

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Acute Cholecystitis Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Type...

Company Profiles: Detailed analysis of the major companies present in the Global Acute Cholecystitis Market.

Available Customizations:

Global Acute Cholecystitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ACUTE CHOLECYSTITIS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Type (Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis)
 - 5.2.2. By Cause (Gall Bladder Stones, Tumor, Bile Duct Blockage, Microbial Infection, Others)
 - 5.2.3. By Diagnostic Procedure (Ultrasonography, Cholescintigraphy, CT Scan, ERCP)

(Endoscopic Retrograde Cholangiopancreatography), Others)

5.2.4. By Treatment (Surgical v/s Non-Surgical)

5.2.5. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)

5.2.6. By Region

5.2.7. By Company (2025)

5.3. Market Map

6. NORTH AMERICA ACUTE CHOLECYSTITIS MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type

6.2.2. By Cause

6.2.3. By Diagnostic Procedure

6.2.4. By Treatment

6.2.5. By End User

6.2.6. By Country

6.3. North America: Country Analysis

6.3.1. United States Acute Cholecystitis Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Type

6.3.1.2.2. By Cause

6.3.1.2.3. By Diagnostic Procedure

6.3.1.2.4. By Treatment

6.3.1.2.5. By End User

6.3.2. Canada Acute Cholecystitis Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Type

6.3.2.2.2. By Cause

6.3.2.2.3. By Diagnostic Procedure

6.3.2.2.4. By Treatment

6.3.2.2.5. By End User

6.3.3. Mexico Acute Cholecystitis Market Outlook

6.3.3.1. Market Size & Forecast

- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Type
 - 6.3.3.2.2. By Cause
 - 6.3.3.2.3. By Diagnostic Procedure
 - 6.3.3.2.4. By Treatment
 - 6.3.3.2.5. By End User

7. EUROPE ACUTE CHOLECYSTITIS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Type
 - 7.2.2. By Cause
 - 7.2.3. By Diagnostic Procedure
 - 7.2.4. By Treatment
 - 7.2.5. By End User
 - 7.2.6. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. Germany Acute Cholecystitis Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Type
 - 7.3.1.2.2. By Cause
 - 7.3.1.2.3. By Diagnostic Procedure
 - 7.3.1.2.4. By Treatment
 - 7.3.1.2.5. By End User
 - 7.3.2. France Acute Cholecystitis Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Type
 - 7.3.2.2.2. By Cause
 - 7.3.2.2.3. By Diagnostic Procedure
 - 7.3.2.2.4. By Treatment
 - 7.3.2.2.5. By End User
 - 7.3.3. United Kingdom Acute Cholecystitis Market Outlook

- 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Type
 - 7.3.3.2.2. By Cause
 - 7.3.3.2.3. By Diagnostic Procedure
 - 7.3.3.2.4. By Treatment
 - 7.3.3.2.5. By End User
- 7.3.4. Italy Acute Cholecystitis Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Type
 - 7.3.4.2.2. By Cause
 - 7.3.4.2.3. By Diagnostic Procedure
 - 7.3.4.2.4. By Treatment
 - 7.3.4.2.5. By End User
- 7.3.5. Spain Acute Cholecystitis Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Type
 - 7.3.5.2.2. By Cause
 - 7.3.5.2.3. By Diagnostic Procedure
 - 7.3.5.2.4. By Treatment
 - 7.3.5.2.5. By End User

8. ASIA PACIFIC ACUTE CHOLECYSTITIS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Type
 - 8.2.2. By Cause
 - 8.2.3. By Diagnostic Procedure
 - 8.2.4. By Treatment
 - 8.2.5. By End User
 - 8.2.6. By Country
- 8.3. Asia Pacific: Country Analysis

- 8.3.1. China Acute Cholecystitis Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Type
 - 8.3.1.2.2. By Cause
 - 8.3.1.2.3. By Diagnostic Procedure
 - 8.3.1.2.4. By Treatment
 - 8.3.1.2.5. By End User
- 8.3.2. India Acute Cholecystitis Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Type
 - 8.3.2.2.2. By Cause
 - 8.3.2.2.3. By Diagnostic Procedure
 - 8.3.2.2.4. By Treatment
 - 8.3.2.2.5. By End User
- 8.3.3. Japan Acute Cholecystitis Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Type
 - 8.3.3.2.2. By Cause
 - 8.3.3.2.3. By Diagnostic Procedure
 - 8.3.3.2.4. By Treatment
 - 8.3.3.2.5. By End User
- 8.3.4. South Korea Acute Cholecystitis Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Type
 - 8.3.4.2.2. By Cause
 - 8.3.4.2.3. By Diagnostic Procedure
 - 8.3.4.2.4. By Treatment
 - 8.3.4.2.5. By End User
- 8.3.5. Australia Acute Cholecystitis Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value

- 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Type
 - 8.3.5.2.2. By Cause
 - 8.3.5.2.3. By Diagnostic Procedure
 - 8.3.5.2.4. By Treatment
 - 8.3.5.2.5. By End User

9. MIDDLE EAST & AFRICA ACUTE CHOLECYSTITIS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Type
 - 9.2.2. By Cause
 - 9.2.3. By Diagnostic Procedure
 - 9.2.4. By Treatment
 - 9.2.5. By End User
 - 9.2.6. By Country
- 9.3. Middle East & Africa: Country Analysis
 - 9.3.1. Saudi Arabia Acute Cholecystitis Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Type
 - 9.3.1.2.2. By Cause
 - 9.3.1.2.3. By Diagnostic Procedure
 - 9.3.1.2.4. By Treatment
 - 9.3.1.2.5. By End User
 - 9.3.2. UAE Acute Cholecystitis Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Type
 - 9.3.2.2.2. By Cause
 - 9.3.2.2.3. By Diagnostic Procedure
 - 9.3.2.2.4. By Treatment
 - 9.3.2.2.5. By End User
 - 9.3.3. South Africa Acute Cholecystitis Market Outlook
 - 9.3.3.1. Market Size & Forecast

- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Type
 - 9.3.3.2.2. By Cause
 - 9.3.3.2.3. By Diagnostic Procedure
 - 9.3.3.2.4. By Treatment
 - 9.3.3.2.5. By End User

10. SOUTH AMERICA ACUTE CHOLECYSTITIS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Type
 - 10.2.2. By Cause
 - 10.2.3. By Diagnostic Procedure
 - 10.2.4. By Treatment
 - 10.2.5. By End User
 - 10.2.6. By Country
- 10.3. South America: Country Analysis
 - 10.3.1. Brazil Acute Cholecystitis Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Type
 - 10.3.1.2.2. By Cause
 - 10.3.1.2.3. By Diagnostic Procedure
 - 10.3.1.2.4. By Treatment
 - 10.3.1.2.5. By End User
 - 10.3.2. Colombia Acute Cholecystitis Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Type
 - 10.3.2.2.2. By Cause
 - 10.3.2.2.3. By Diagnostic Procedure
 - 10.3.2.2.4. By Treatment
 - 10.3.2.2.5. By End User
 - 10.3.3. Argentina Acute Cholecystitis Market Outlook

- 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Type
 - 10.3.3.2.2. By Cause
 - 10.3.3.2.3. By Diagnostic Procedure
 - 10.3.3.2.4. By Treatment
 - 10.3.3.2.5. By End User

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments

13. GLOBAL ACUTE CHOLECYSTITIS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

- 15.1. Boston Scientific Corporation
 - 15.1.1. Business Overview
 - 15.1.2. Products & Services
 - 15.1.3. Recent Developments
 - 15.1.4. Key Personnel
 - 15.1.5. SWOT Analysis
- 15.2. Fresenius Kabi AG

- 15.3. Pfizer Inc
- 15.4. Teva Pharmaceutical Industries Ltd.
- 15.5. Glenmark Pharmaceuticals Limited
- 15.6. Merck & Co. Inc.
- 15.7. Becton, Dickinson and Company
- 15.8. Simulab Corporation
- 15.9. AbbVie Inc.
- 15.10. Fortimedix Surgical BV

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER

I would like to order

Product name: Acute Cholecystitis Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Type (Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis) By Cause (Gall Bladder Stones, Tumor, Bile Duct Blockage, Microbial Infection, Others) By Diagnostic Procedure (Ultrasonography, Cholescintigraphy, CT Scan, ERCP (Endoscopic Retrograde Cholangiopancreatography), Others) By Treatment (Surgical v/s Non-Surgical) By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others) By Region & Competition, 2021-2031F

Product link: <https://marketpublishers.com/r/ABAAF3BC275BEN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABAAF3BC275BEN.html>